- •PROGRESS IN BRAIN RESEARCH
- •List of Contributors
- •Preface
- •Epidemiology of primary glaucoma: prevalence, incidence, and blinding effects
- •Introduction
- •Prevalence of glaucoma
- •PAC suspect
- •PACG
- •Incidence of glaucoma
- •Blinding effects of glaucoma
- •Abbreviations
- •Acknowledgment
- •References
- •Predictive models to estimate the risk of glaucoma development and progression
- •Risk assessment in ocular hypertension and glaucoma
- •Risk factors for glaucoma development
- •Intraocular pressure
- •Corneal thickness
- •Cup/disc ratio and pattern standard deviation
- •The need for predictive models
- •Predictive models for glaucoma development
- •Predictive models for glaucoma progression
- •Limitations of predictive models
- •References
- •Intraocular pressure and central corneal thickness
- •Main text
- •References
- •Angle-closure: risk factors, diagnosis and treatment
- •Introduction
- •Mechanism
- •Other causes of angle closure
- •Risk factors
- •Age and gender
- •Ethnicity
- •Ocular biometry
- •Genetics
- •Diagnosis
- •Acute primary angle closure
- •Angle assessment in angle closure
- •Gonioscopy technique
- •Ultrasound biomicroscopy (UBM)
- •Scanning peripheral anterior chamber depth analyzer (SPAC)
- •Management
- •Acute primary angle closure
- •Medical therapy
- •Argon laser peripheral iridoplasty (ALPI)
- •Laser peripheral iridotomy (PI)
- •Lens extraction
- •Monitoring for subsequent IOP rise in eyes with APAC
- •Fellow eye of APAC
- •Chronic primary angle-closure glaucoma (CACG)
- •Laser peripheral iridotomy
- •Laser iridoplasty
- •Medical therapy
- •Trabeculectomy
- •Lens extraction
- •Combined lens extraction and trabeculectomy surgery
- •Goniosynechialysis
- •Summary
- •List of abbreviations
- •References
- •Early diagnosis in glaucoma
- •Introduction
- •History and examination
- •Quantitative tests and the diagnostic process
- •Pretest probability
- •Test validity
- •Diagnostic test performance
- •Posttest probability
- •Combing test results
- •Selective tests of visual function
- •Early glaucoma diagnosis from quantitative test results
- •Progression to make a diagnosis
- •Conclusions
- •Abbreviations
- •References
- •Monitoring glaucoma progression
- •Introduction
- •Monitoring structural damage progression
- •Monitoring functional damage progression
- •Abbreviations
- •References
- •Standard automated perimetry and algorithms for monitoring glaucoma progression
- •Standard automated perimetry
- •Global indices
- •HFA: MD, SF, PSD, CPSD
- •Octopus indices: MD, SF, CLV
- •OCTOPUS seven-in-one report (Fig. 2)
- •SAP VF assessment: full-threshold strategy
- •SAP VF defects assessment: OHTS criteria
- •SAP VF defects assessment: AGIS criteria
- •SAP VF defects assessment: CIGTS
- •Fastpac
- •Swedish interactive threshold algorithm
- •SAP VF assessment: the glaucoma staging system
- •SAP: interocular asymmetries in OHTS
- •SAP, VF progression
- •SAP: the relationship to other functional and structural diagnostic tests in glaucoma
- •SAP, FDP-Matrix
- •SAP, SWAP, HPRP, FDT
- •SAP: the relationship between function and structure
- •SAP, confocal scanning laser ophthalmoscopy, SLP-VCC
- •SAP, optical coherence tomography
- •SAP and functional magnetic resonance imaging
- •References
- •Introduction
- •Retinal ganglion cells: anatomy and function
- •Is glaucoma damage selective for any subgroup of RGCs?
- •Segregation
- •Isolation
- •FDT: rationale and perimetric techniques
- •SWAP: rationale and perimetric techniques
- •FDT: clinical data
- •SWAP: clinical data
- •Clinical data comparing FDT and SWAP
- •Conclusions
- •References
- •Scanning laser polarimetry and confocal scanning laser ophthalmoscopy: technical notes on their use in glaucoma
- •The GDx scanning laser polarimeter
- •Serial analysis
- •Limits
- •The Heidelberg retinal tomograph
- •Limits
- •Conclusions
- •References
- •The role of OCT in glaucoma management
- •Introduction
- •How OCT works
- •How OCT is performed
- •Evaluation of RNFL thickness
- •Evaluation of optic disc
- •OCT in glaucoma management
- •New perspective
- •Abbreviations
- •References
- •Introduction
- •Technology
- •Visual stimulation
- •Reproducibility and habituation of RFonh
- •Retinal neural activity as assessed from the electroretinogram (ERG)
- •The Parvo (P)- and Magno (M)-cellular pathways
- •Physiology
- •Magnitude and time course of RFonh in humans
- •Varying the parameters of the stimulus on RFonh
- •Luminance versus chromatic modulation
- •Frequency
- •Effect of pattern stimulation
- •Neurovascular coupling in humans
- •Clinical application
- •RFonh in OHT and glaucoma patients
- •Discussion
- •FLDF and neurovascular coupling in humans
- •Comments on clinical application of FLDF in glaucoma
- •Conclusions and futures directions
- •Acknowledgements
- •References
- •Advances in neuroimaging of the visual pathways and their use in glaucoma
- •Introduction
- •Conventional MR imaging and the visual pathways
- •Diffusion MR imaging
- •Functional MR imaging
- •Proton MR spectroscopy
- •References
- •Primary open angle glaucoma: an overview on medical therapy
- •Introduction
- •When to treat
- •Whom to treat
- •Genetics
- •Race
- •Ocular and systemic abnormalities
- •Tonometry and pachymetry
- •How to treat
- •Beta-blockers
- •Prostaglandins
- •Alpha-agonists
- •Carbonic anhydrase inhibitors (CAIs)
- •Myotics
- •Fixed combinations
- •References
- •The treatment of normal-tension glaucoma
- •Introduction
- •Epidemiology
- •Clinical features
- •Optic disk
- •Central corneal thickness
- •Disease course
- •Risk factors
- •Intraocular pressure
- •Local vascular factors
- •Immune mechanisms
- •Differential diagnosis
- •Diagnostic evaluation
- •Therapy
- •IOP reduction
- •Systemic medications
- •Neuroprotection
- •Noncompliance
- •Genetics of NTG
- •Abbreviations
- •References
- •The management of exfoliative glaucoma
- •Introduction
- •Epidemiology
- •Ocular and systemic associations
- •Ocular associations
- •Systemic associations
- •Pathogenesis of exfoliation syndrome
- •Mechanisms of glaucoma development
- •Management
- •Medical therapy
- •Laser surgery
- •Operative surgery
- •Future treatment of exfoliation syndrome and exfoliative glaucoma
- •Treatment directed at exfoliation material
- •References
- •Laser therapies for glaucoma: new frontiers
- •Background
- •Laser iridotomy
- •Indications
- •Contraindications
- •Patient preparation
- •Technique
- •Nd:YAG laser iridectomy
- •Argon laser iridectomy
- •Complications
- •LASER trabeculoplasty
- •Treatment technique
- •Mechanism of action
- •Indications for treatment
- •Contraindications to treatment
- •Patient preparation and postoperative follow-up
- •Complications of the treatment
- •Selective laser trabeculoplasty
- •Results
- •LASER iridoplasty
- •Indications
- •Contraindications
- •Treatment technique
- •Complications
- •LASER cyclophotocoagulation
- •Introduction
- •Indications and contraindications
- •Patient preparation
- •Transpupillary cyclophotocoagulation
- •Endoscopic cyclophotocoagulation
- •Transscleral cyclophotocoagulation
- •Transscleral noncontact cyclophotocoagulation
- •Transscleral contact cyclophotocoagulation
- •Complications
- •Excimer laser trabeculotomy
- •References
- •Modulation of wound healing during and after glaucoma surgery
- •The process of wound healing
- •Using surgical and anatomical principles to modify therapy
- •Growth factors
- •Cellular proliferation and vascularization
- •Cell motility, matrix contraction and synthesis
- •Drug delivery
- •Future directions: total scarring control and tissue regeneration
- •Acknowledgments
- •References
- •Surgical alternative to trabeculectomy
- •Introduction
- •Deep sclerectomy
- •Viscocanalostomy
- •Conclusions
- •References
- •Modern aqueous shunt implantation: future challenges
- •Background
- •Current shunts and factors affecting their function
- •Shunt-related factors
- •Surface area
- •Plate material
- •Valved versus non-valved
- •Commercially available devices
- •Comparative studies
- •Patient and ocular factors
- •Severity of glaucoma damage
- •Tolerance of topical ocular hypotensive medications
- •Aqueous hyposecretion
- •Previous ocular surgery
- •Scleral thinning
- •Patient cooperation for and tolerance of potential slit-lamp interventions
- •Future challenges
- •Predictability
- •Cataract formation
- •The long-term effect on the cornea
- •References
- •Model systems for experimental studies: retinal ganglion cells in culture
- •Mixed RGCs in culture
- •Retinal explants
- •Glial cultures
- •RGC-5 cells
- •Differentiation of RGC-5 cells
- •RGC-5 cell neurites
- •Advantages and disadvantages of culture models
- •References
- •Rat models for glaucoma research
- •Rat models for glaucoma research
- •Use of animal models for POAG
- •Suitability of the rat for models of optic nerve damage in POAG
- •Methods for measuring IOP in rats
- •General considerations for measuring IOP in rats
- •Assessing optic nerve and retina damage
- •Experimental methods of producing elevated IOP
- •Laser treatment of limbal tissues
- •Episcleral vein cautery
- •Conclusions
- •Abbreviations
- •Acknowledgements
- •References
- •Mouse genetic models: an ideal system for understanding glaucomatous neurodegeneration and neuroprotection
- •Introduction
- •The mouse as a model system
- •Mice are suitable models for studying IOP elevation in glaucoma
- •Tools for glaucoma research
- •Accurate IOP measurements are fundamental to the study of glaucoma
- •The future of IOP assessment
- •Assessment of RGC function
- •Mouse models of glaucoma
- •Primary open-angle glaucoma
- •MYOC
- •OPTN
- •Strategies for developing new models of POAG
- •Developmental glaucoma
- •Pigmentary glaucoma
- •Experimentally induced models of glaucoma
- •Mouse models to characterize processes involved in glaucomatous neurodegeneration
- •Similar patterns of glaucomatous damage occur in humans and mice
- •The lamina cribrosa is an important site of early glaucomatous damage
- •An insult occurs to the axons of RGCs within the lamina in glaucoma
- •What is the nature of the insult at the lamina?
- •Other changes occur in the retina in glaucoma
- •PERG and complement
- •Using mouse models to develop neuroprotective strategies
- •Somal protection
- •Axonal protection
- •Erythropoietin administration
- •Radiation-based treatment
- •References
- •Clinical trials in neuroprotection
- •Introduction
- •Methods of clinical studies
- •Issues in the design and conduct of clinical trials
- •Clinical trials of neuroprotection
- •Clinical trials of neuroprotection in ophthalmology
- •Endpoints
- •Neuroprotection and glaucoma
- •Conclusions
- •Abbreviations
- •References
- •Pathogenesis of ganglion ‘‘cell death’’ in glaucoma and neuroprotection: focus on ganglion cell axonal mitochondria
- •Introduction
- •Retinal ganglion cells and mitochondria
- •Possible causes for ganglion cell death in glaucoma
- •Mitochondrial functions and apoptosis
- •Mitochondrial function enhancement and the attenuation of ganglion cell death
- •Creatine
- •Nicotinamide
- •Epigallocatechin gallate
- •Conclusion
- •References
- •Astrocytes in glaucomatous optic neuropathy
- •Introduction
- •Quiescent astrocytes
- •Reactive astrocytes in glaucoma
- •Signal transduction in glaucomatous astrocytes
- •Protein tyrosine kinases (PTKs)
- •Serine/threonine protein mitogen-activated kinases (MAPKs)
- •G protein-coupled receptors
- •Ras superfamily of small G proteins
- •Astrocyte migration in the glaucomatous optic nerve head
- •Cell adhesion of ONH astrocytes
- •Connective tissue changes in the glaucomatous optic nerve head
- •Extracellular matrix synthesis by ONH astrocytes
- •Extracellular matrix degradation by reactive astrocytes
- •Oxidative stress in ONH astrocytes
- •Conclusions
- •Acknowledgments
- •References
- •Glaucoma as a neuropathy amenable to neuroprotection and immune manipulation
- •Glaucoma as a neurodegenerative disease
- •Oxidative stress and free radicals
- •Excessive glutamate, increased calcium levels, and excitotoxicity
- •Deprivation of neurotrophins and growth factors
- •Abnormal accumulation of proteins
- •Pharmacological neuroprotection for glaucoma
- •Protection of the retinal ganglion cells involves the immune system
- •Searching for an antigen for potential glaucoma therapy
- •Concluding remarks
- •References
- •Oxidative stress and glaucoma: injury in the anterior segment of the eye
- •Introduction
- •Oxidative stress
- •Trabecular meshwork
- •IOP increase and free radicals
- •Glaucomatous cascade
- •Nitric oxide and endothelins
- •Extracellular matrix
- •Metalloproteinases
- •Other factors of interest
- •Therapeutic and preventive substances of interest in glaucoma
- •Ginkgo biloba extract
- •Green tea
- •Ginseng
- •Memantine and its derivates
- •Conclusions
- •Abbreviations
- •References
- •Conclusions on neuroprotective treatment targets in glaucoma
- •Acknowledgments
- •References
- •Involvement of the Bcl2 gene family in the signaling and control of retinal ganglion cell death
- •Introduction
- •Intrinsic apoptosis vs. extrinsic apoptosis
- •The Bcl2 family of proteins
- •The requirement of BAX for RGC soma death
- •BH3-only proteins and the early signaling of ganglion cell apoptosis
- •Conclusion
- •Abbreviations
- •Acknowledgments
- •References
- •Assessment of neuroprotection in the retina with DARC
- •Introduction
- •DARC
- •Introducing the DARC technique
- •Annexin 5-labeled apoptosis and ophthalmoloscopy
- •Detection of RGC apoptosis in glaucoma-related animal models with DARC
- •Assessment of glutamate modulation with DARC
- •Glutamate at synaptic endings
- •Glutamate excitotoxicity in glaucoma
- •Assessment of coenzyme Q10 in glaucoma-related models with DARC
- •Summary
- •Abbreviations
- •Acknowledgment
- •References
- •Potential roles of (endo)cannabinoids in the treatment of glaucoma: from intraocular pressure control to neuroprotection
- •Introduction
- •The endocannabinoid system in the eye
- •The IOP-lowering effects of endocannabinoids
- •Endocannabinoids and neuroprotection
- •Conclusions
- •References
- •Glaucoma of the brain: a disease model for the study of transsynaptic neural degeneration
- •Retinal ganglion cells, retino-geniculate neurons
- •Lateral geniculate nucleus
- •Mechanisms of RGC injury in glaucoma
- •Transsynaptic degeneration of the lateral geniculate nucleus in glaucoma
- •Neural degeneration in magno-, parvo-, and koniocellular LGN layers
- •Visual cortex in glaucoma
- •Neuropathology of glaucoma in the visual pathways in the human brain
- •Mechanisms of glaucoma damage in the central visual pathways
- •Implications of central visual system injury in glaucoma
- •Conclusion
- •Acknowledgments
- •References
- •Clinical relevance of optic neuropathy
- •Is there a remodeling of retinal circuitry?
- •Behavioral consequences of glaucoma
- •Glaucoma as a neurodegenerative disease versus neuroplasticity and adaptive changes
- •Future directions
- •Acknowledgment
- •References
- •Targeting excitotoxic/free radical signaling pathways for therapeutic intervention in glaucoma
- •Introduction
- •Channel properties of NMDA receptors correlated with excitotoxicity
- •Downstream signaling cascades after overactivation of NMDA receptors
- •Relevance of excitotoxicity to glaucoma
- •Therapeutic approaches to prevent RGC death by targeting the pathways involved in NMDA excitotoxicity
- •Drugs targeting NMDA receptors
- •Kinetics of NMDA receptor antagonists
- •Memantine
- •NitroMemantines
- •Drugs targeting downstream signaling molecules in NMDA-induced cell death pathways
- •p38 MAPK inhibitors
- •Averting caspase-mediated neurodegeneration
- •Abbreviations
- •Acknowledgments
- •References
- •Stem cells for neuroprotection in glaucoma
- •Introduction
- •Glaucoma as a model of neurodegenerative disease
- •Why use stem cells for neuroprotective therapy?
- •Stem cell sources
- •Neuroprotection by transplanted stem cells
- •Endogenous stem cells
- •Key challenges
- •Conclusion
- •Abbreviations
- •Acknowledgments
- •References
- •The relationship between neurotrophic factors and CaMKII in the death and survival of retinal ganglion cells
- •Introduction
- •Glaucoma and the RGCs
- •Are other retinal cells affected in glaucoma?
- •Retinal ischemia related glaucoma
- •Excitotoxicity and the retina
- •Signal transduction
- •NMDA receptor antagonists and CaMKII
- •Caspase-3 activation in NMDA-induced retinal cell death and its inhibition by m-AIP
- •BDNF and neuroprotection of RGCs
- •Summary and conclusions
- •Abbreviations
- •Acknowledgments
- •References
- •Evidence of the neuroprotective role of citicoline in glaucoma patients
- •Introduction
- •Patients: selection and recruitment criteria
- •Pharmacological treatment protocol
- •Methodology of visual function evaluation: electrophysiological examinations
- •PERG recordings
- •VEP recordings
- •Statistic evaluation of electrophysiological results
- •Electrophysiological (PERG and VEP) responses in OAG patients after the second period of evaluation
- •Effects of citicoline on retinal function in glaucoma patients: neurophysiological implications
- •Effects of citicoline on neural conduction along the visual pathways in glaucoma patients: neurophysiological implications
- •Possibility of neuroprotective role of citicoline in glaucoma patients
- •Conclusive remarks
- •Abbreviations
- •References
- •Neuroprotection: VEGF, IL-6, and clusterin: the dark side of the moon
- •Neuroprotection: VEGF-A, a shared growth factor
- •VEGF-A isoforms
- •VEGF-A receptors
- •Angiogenesis, mitogenesis, and endothelial survival
- •Neurotrophic and neuroprotective effect
- •Intravitreal VEGF inhibition therapy and neuroretina toxicity
- •Neuroprotection: clusterin, a multifunctional protein
- •Clusterin/ApoJ: a debated physiological role
- •Clusterin and diseases
- •Clusterin and the nervous system
- •Neuroprotection: IL-6, VEGF, clusterin, and glaucoma
- •Rational basis for the development of coenzyme Q10 as a neurotherapeutic agent for retinal protection
- •Introduction
- •Ischemia model
- •Neuroprotective effect of Coenzyme Q10 against cell loss yielded by transient ischemia in the RGC layer
- •Retinal ischemia and glutamate
- •Coenzyme Q10 minimizes glutamate increase induced by ischemia/reperfusion
- •Summary
- •Acknowledgment
- •References
- •17beta-Estradiol prevents retinal ganglion cell loss induced by acute rise of intraocular pressure in rat
- •Methods
- •Morphometric analysis
- •Microdialysis
- •Drug application
- •Statistical analysis
- •Results
- •17beta-Estradiol pretreatment minimizes RGC loss
- •Discussion
- •Acknowledgment
Normalized superior area: This parameter examines the data obtained exclusively in the superior part of the ellipse; higher value represents a physiological condition, while a lower value indicates an RNFL loss.
Normalized inferior area: This parameter examines the data obtained exclusively in the inferior part of the ellipse; higher value represents a physiological condition, while a lower value indicates an RNFL loss.
Ellipse standard deviation: It indicates the standard deviation of the values obtained in the calculation area.
Serial analysis
In the serial analysis are included up to four scansions of the same eye reported chronologically, in order to allow an evaluation of RNFL variations with time:
TSNIT confrontation graph: It compares, by means of a superimposition, the TSNIT graphs of two scansion of the same eye, taken during two consecutive visits. With this graph, it is possible to evaluate the variations of the RNFL thickness with time.
TSNIT serial analysis graph: It compares, by means of a superimposition, the TSNIT graphs of two, three, or four subsequent scansions of the same eye, taken during different visits. With this graph, it is possible to evaluate the variations of the RNFL thickness with time.
Deviation from reference map: It shows the variation of the RNFL thickness occurring during different visits. The colored areas and dots indicate the possible significant clinical variation. The colored legend defined variations with 20 mm increase.
Limits
The GDx, in the latest version called GDx-VCC, shows a high reproducibility with a good discrimination within normal and glaucomatous subjects (Greenfield et al., 2002; Weinreb et al., 2003;
131
Brusini et al., 2005), and a close correlation between VF defects and RNFL damage (Bowd et al., 2003; Reus and Lemij, 2005).
However, the examination shows some limitation due to the ellipse localization that is operator dependent; furthermore, the interpretation of the results needs to be integrated with the clinical examination to achieve a precise diagnosis. There are still some limitations of the use of this instrument, for example, corneal refractive surgery (Choplin et al., 2005; Zangwill et al., 2005), lens surgery, presence of chorioretinal atrophy or scars, presence of myelinic fibers; all these conditions may interfere with birefringence. In addition, corneal opacity, pupil diameter lower than 2 mm, and significant vitreal opacities do not allow to perform the test.
The NFI can be considered positive when the value obtained is equal to or higher than 40 and this index has a sensitivity of 76.8% and a reproducibility of 89.1% (Colen et al., 2004).
Also, the progression of the damage should be considered with caution, since it was not demonstrated that variations from two consecutive examinations are certainly due to the progression of the disease rather than due to a physiological variation (Boehm et al., 2003).
The Heidelberg retinal tomograph
The HRT (Heidelberg Engineering, Heidelberg, Germany) is specifically designed to analyze the optic nerve head and gives an indirect evaluation of the RNFL. It is a confocal laser that uses a red diode laser of 670 nm wavelength. It performs a three-dimensional evaluation of the characteristics of the optic nerve head and peripapillary retina, with no need for mydriasis. It captures, in a time interval between 1.2 and 4.5 s, 32 optical pictures parallel to the retinal plane, analyzing the optic disk up to 151.
The scansions are obtained by a periodic deflection of the laser beam, by means of swinging mirrors, and using the confocal characteristics of the instrument, so that only the light coming from a determined focal plane is captured by the detector. The light coming from contiguous plans
132
is discarded through two inner diaphragms, one of which is in front of the laser source and the other in front of the detector. In this way, the light from each retinal point is reflected toward the detector and is represented as a pixel on the screen. Each pixel height is automatically calculated with respect to the reference plane, located 50 mm behind the papillomacular bundle (Vihanninjoki et al., 2002).
A topographical image is acquired and, subsequently, a three-dimensional image of the optic nerve is obtained by computer analysis.
Before the image acquisition, it is important to upload patients’ personal and clinical data, corneal ray of curvature, and refraction: myopia and hyperopia of up to 11 diopters can be corrected, while high astigmatisms can be corrected by the use of adjunctive lenses. In patients with higher refractive errors, it is not possible to perform the examination.
At the start of the examination, the instrument makes an automatic scansion on 32 different planes on the papillary area (from a prepapillary to a retrolaminar plane) so that 32 bidimensional images are obtained.
The examination is repeated thrice so that three different images are obtained. From these images, the computer elaborates a mean topographic image 384 384 pixels wide, with three-dimensional reconstruction of the optic disk.
The instrument is able to evaluate the image quality by means of two quality parameters: interscan standard deviation (i.e., the mean test– retest variability: SD) and the mean confidence interval (CI) of the highest of the three images (good W20 mm, sufficient W50 mm). Furthermore, the instrument is able to give suggestions about the acquisition and to correct the scan depth and/or the refractive defects.
The mean image is shown with two maps: topographic map and reflectivity map. In the topographic map, the depth value is expressed with several colors (blue green is the deepest area; in the reflectivity map the reflectivity of each pixel is shown). On the topographic image, the operator can delimit the optic nerve head (contour line) along the inner border of the Elschnig’s scleral ring.
Fig. 8. HRT three-dimensional image of optic nerve head and peripapillary area.
Following this demarcation, the instrument automatically chooses a standard reference plane localized 50 mm under the mean peripapillary retinal thickness, along the contour line in the temporal sector between 3501 and 3561. This reference plane utilizes most part of the considered parameters circumscribed within the two areas of the optic disk: above the neuroretinal ring (green color) and below the excavation zone (red color).
The three-dimensional analysis allows obtaining planimetric and volumetric parameters (23 global and 13 partial) related to the optic nerve head and the RNFL measurement on the optical nerve head external border (Fig. 8).
The principal analyses obtained are the following:
Cross-section analysis: It allows to evaluate the three-dimensional aspect of the optic disk along one of the three Cartesian axes by means of a cursor.
Topographic map: It gives, in the absolute value or in mean7standard deviation, the height of each pixel analyzed by the system.
RNFL thickness diagram: It analyzes the thickness variation with double hump image from the temporal to the inferior sectors (TSNIT graph).
Stereometric parameters of the optic nerve head:
1.Dependent on the reference plane: cup area, cup/disk area ratio, rim area, cup volume, rim volume, RNFL crosssectional area, and mean RNFL thickness.
2.Independent of the reference plane: disk area, height variation contour, maximum
contour elevation and depression, CLM temporal superior and temporal inferior, mean cup depth, maximum cup depth, and cup shape measurement (morphological index of the cup or CSM) (Table 2).
Moorfields regression analysis (MRA): It compares the volumes of two stereometric parameters (rim and cup) in six papillary sectors with values obtained from normal
subjects and early glaucoma patients, with optic disk diameter between 1.2 and 2.8 mm2.
Data obtained from this classification give a good specificity and sensibility (Wollstein et al., 1998; Miglior et al., 2003) and can be shown in graphic and numerical details in comparison with the predictive values per age and optic disk diameter in the 95.0, 99.0, and 99.9% of the normative database. The graphs give quick visualization of the site and entity of the damage, evaluated according to a score in normal, borderline, and outline (Fig. 9).
133
Interactive measurement: It gives an interactive horizontal and vertical profile of the optic nerve (Fig. 10).
Among the instrument functions, it is worth mentioning the possibility to study the glaucoma progression with time, which depends on the reproducibility of the several examinations performed.
The possibility to automatically display the previous contour line increases the reproducibility of the test (Verdonck et al., 2002; Tan et al., 2003) and, therefore, gives to the instrument the possibility to objectively analyze the papillary damage progression, by two different measurements:
1.Stereometric progression chart: Two sequential examinations are necessary; it also evaluates the variation of single stereometric parameters with time. The stability of the disease is indicated by the average normalized parameters value of 0, while the progression of the disease gives a value of 0.05. The
Table 2. HRT stereometric parameters of the optic nerve head
Parameters |
|
Predefined segments |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Global |
Temporal |
tmp/sup |
tmp/inf |
Nasal |
nsl/sup |
nsl/inf |
|
|
|
|
|
|
|
|
|
Disk area (mm2) |
1.490 |
0.344 |
0.209 |
0.208 |
0.355 |
0.185 |
0.189 |
|
Cup area (mm2) |
0.317 |
0.199 |
0.062 |
0.035 |
0.007 |
0.008 |
0.006 |
|
Rim area (mm2) |
1.173 |
0.146 |
0.147 |
0.173 |
0.348 |
0.176 |
0.183 |
|
Cup/disk area ratio |
0.213 |
0.577 |
0.297 |
0.171 |
0.019 |
0.044 |
0.033 |
|
Rim/disk area ratio |
0.787 |
0.423 |
0.703 |
0.829 |
0.981 |
0.956 |
0.967 |
|
Cup volume (mm3) |
0.065 |
0.036 |
0.017 |
0.007 |
0.002 |
0.002 |
0.001 |
|
Rim volume (mm3) |
0.326 |
0.008 |
0.028 |
0.042 |
0.125 |
0.069 |
0.053 |
|
Mean Cup depth (mm) |
0.198 |
0.235 |
0.250 |
0.166 |
0.129 |
0.192 |
0.070 |
|
Maximum cup depth (mm) |
0.701 |
0.692 |
0.724 |
0.613 |
0.675 |
0.710 |
0.490 |
|
Height variation contour (mm) |
0.378 |
0.108 |
0.231 |
0.180 |
0.089 |
0.070 |
0.025 |
|
Cup shape measure (mm) |
|
0.298 |
0.178 |
0.168 |
0.341 |
0.519 |
0.403 |
0.482 |
Mean RNFL thickness (mm) |
0.254 |
0.065 |
0.242 |
0.264 |
0.349 |
0.389 |
0.312 |
|
RNFL cross-sectional area (mm2) |
1.099 |
0.068 |
0.138 |
0.148 |
0.365 |
0.214 |
0.173 |
|
Horizontal cup/disk ratio |
0.486 |
– |
– |
– |
– |
– |
– |
|
Vertical cup/disk ratio |
0.301 |
– |
– |
– |
– |
– |
– |
|
Maximum contour elevation (mm) |
|
0.085 |
– |
– |
– |
– |
– |
– |
Maximum contour depression (mm) |
0.293 |
– |
– |
– |
– |
– |
– |
|
CLM temporal–superior (mm) |
0.177 |
– |
– |
– |
– |
– |
– |
|
CLM temporal–inferior (mm) |
0.198 |
– |
– |
– |
– |
– |
– |
|
Average variability (SD) (mm) |
0.013 |
– |
– |
– |
– |
– |
– |
|
Reference height (mm) |
0.330 |
– |
– |
– |
– |
– |
– |
|
FSM discriminant function value |
2.076 |
– |
– |
– |
– |
– |
– |
|
RB discriminant function value |
1.539 |
– |
– |
– |
– |
– |
– |
|
|
|
|
|
|
|
|
|
|
134
Fig. 9. HRT Moorfields regression analysis graphs.
normalized parameters can be analyzed singularly and globally or with three different sector combinations: superotemporal sector (from 451 to 901), inferotemporal sector (from901 to 451), superior sector (from 22.51 to 112.51), inferior sector (from 112.51 to 22.51), superior hemisphere (from 01 to 1801), and inferior hemisphere (from 01 to1801). Studying the variation of single parameters, the instrument can evaluate a difference of values between baseline and follow-up (Fig. 11).
2.Progression analysis: Three sequential examinations are necessary. It is independent of the contour line and evaluates the modification of values from each pixel allowing the formation of the three-dimensional image (Chauhan et al., 2000). By studying the local variability, the test indicates if a change can be due to a modification of the parameter (change probability), which indicates a significant variation if lower than 0.05 compared with the basal examination.
In the progression analysis, the modified areas, with respect to previous evaluations, are shown with red pixels in the refractive map; a variation is considered significant if an area of at least 20 adjacent pixels is involved. Three examinations must be of excellent quality and perfectly aligned to perform the correct analyses, since the worst is the quality, the higher the variability.
It remains difficult to bring into evidence the damage progression because the criteria to state it are still not precise (Fig. 12). Recent studies have brought into evidence a long-term fluctuation of HRT parameters similar to that occurring with SAP (Chauhan et al., 2001; Funk and Mueller, 2003). The present version of the HRT, with the software 3.0 (HRT III), offers an option for alternative analysis that does not require placement of a contour line that also may introduce interoperator variability (Garway-Heath et al., 1999; Iester et al., 2001; Miglior et al., 2002).
Although the normative database in HRT II included 349 subject for the stereoscopic
135
Fig. 10. HRT interactive measurement graph.
parameters and 110 subjects for the MRA, the HRT III normative database included 733 healthy Caucasian eyes and 215 healthy African eyes (Burgansky-Eliash et al., 2007). Based on the enlarged database, the equations of the MRA were modified between HRT II and HRT III.
The technique provides stereometric data by applying an automatic model of the optic nerve
head shape, and the resultant morphological parameters are analyzed by a machine-learning classifier (relevance vector machine) resulting in a glaucoma probability score (GPS).
The GPS analysis provides a disease probability value based on the three-dimensional shape of the optic nerve and RNFL, and this classification represents the likelihood of glaucoma and not
136
Fig. 11. HRT stereometric progression chart.
Fig. 12. HRT progression analysis chart.
